SCHEMBL14099787

SCHEMBL14099787

CCOC(=O)c1cc(NC(=O)OC(C)(C)C)cn1CCCO

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.39
MAPT P10636 3/20 0.36
ALDH1A1 P00352 1/20 0.36
KDM4E B2RXH2 3/20 0.35
P2RY12 Q9H244 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
NPC1 O15118 3/20 0.34
RAB9A P51151 3/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 1/20 0.34
CYP2C19 P33261 1/20 0.34
MAPK14 Q16539 1/20 0.34
ACHE P22303 1/20 0.34
BACE1 P56817 1/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA9 Q16790 1/20 0.34
CRHBP P24387 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24630430 0.90 CNR2 (0.48) CNR2MAPTALDH1A1KDM4EP2RY12
SCHEMBL27197336 0.88 CNR2 (0.40) CNR2MAPTKDM4EP2RY12NPC1
SCHEMBL24630357 0.88 CNR2 (0.40) CNR2MAPTKDM4EP2RY12NPC1
SCHEMBL16348810 0.86 CNR2 (0.37) CNR2TDP1MAPK14ACHEBACE1
SCHEMBL14262464 0.86 CNR2 (0.40) CNR2TDP1MAPK14ACHEBACE1
SCHEMBL12513701 0.86 CNR2 (0.42) CNR2TDP1MAPK14ACHEBACE1
SCHEMBL24630431 0.84 CNR2 (0.37) CNR2MAPTKDM4EP2RY12NPC1
SCHEMBL7055806 0.83 P2RY12 (0.47) MAPTALDH1A1KDM4EP2RY12NPC1
SCHEMBL7613860 0.81 TP53 (0.38) MAPTALDH1A1KDM4E
SCHEMBL24630359 0.80 CNR2 (0.35) CNR2MAPTKDM4EP2RY12NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200465-A1 Substituted with a morpholine group through amido heterocylic groups; interfering with the expression of genes essential for the pathogen's proliferation; treating viral and protozoan infections in mammals GENESOFT PHARMACEUTICALS, INC. (US) 2008-08-21 US disclosed
US-20080200465-A1 Substituted with a morpholine group through amido heterocylic groups; interfering with the expression of genes essential for the pathogen's proliferation; treating viral and protozoan infections in mammals GENESOFT PHARMACEUTICALS, INC. (US) 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200465-A1 Substituted with a morpholine group through amido heterocylic groups; interfering with the expression of genes essential for the pathogen's proliferation; treating viral and protozoan infections in mammals IRF3, BCL3, L3MBTL3 CNR2 281/4885MAPT 4789/4885ALDH1A1 3117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.